TABLE 2.

Baseline Demographic and Clinical Characteristics^a

	Fingolimod		Dimethyl Fumarate		Teriflunomide		P Valueb
Patients, n (%)	195	13.0	1,160	77.4	143	9.5
Age, mean (SD)	44.4	10.6	48.1	10.6	53.2	9.9	< 0.001
Gender, n (%)							0.048
Male	32	16.4	284	24.5	33	23.1
Female	163	83.6	876	75.5	110	76.9
Plan type, n (%)							0.254
Fee-for-service	160	82.1	978	84.3	127	88.8
HMO and POS capitation	20	10.3	118	10.2	13	9.1
Unknown	15	7.7	64	5.5	3	2.1
Region, n (%)							0.477
Northeast	38	19.5	273	23.5	26	18.2
North Central	50	25.6	262	22.6	40	28.0
South	62	31.8	324	27.9	41	28.7
West	41	21.0	274	23.6	35	24.5
Unknown	4	2.1	27	2.3	1	0.7
Previous injectable/infused DMT use, n (%)	130	66.7	838	72.2	91	63.6	0.043
Previous other oral DMT use, n (%)	1	0.5	39	3.4	6	4.2	0.073
MS relapse, mean (SD)	0.33	0.61	0.37	0.72	0.50	0.86	0.198
≥1 MS relapse, n (%)	53	27.2	310	26.7	47	32.9	0.298
Resource utilization, n (%)
All-cause hospitalization	23	11.8	128	11.0	18	12.6	0.833
All-cause ER visit	57	29.2	307	26.5	34	23.8	0.523
All-cause office visit	194	99.5	1,155	99.6	142	99.3	1.000
MS-related hospitalization	10	5.1	43	3.7	9	6.3	0.259
MS-related ER visit	26	13.3	152	13.1	23	16.1	0.614
MS-related office visit	191	97.9	1,134	97.8	141	98.6	0.823
Charlson Comorbidity Index score, mean (SD)	0.33	0.86	0.44	0.90	0.68	1.28	0.003
Elixhauser Comorbidity Index score, mean (SD)	2.11	1.47	2.08	1.28	2.42	1.97	0.579

^aThe demographic information was measured at index date. Disease history, including previous DMT use and resource utilization and comorbidity information, was measured 12 months before index date.

^bChi-square tests (Fisher exact test was employed when at least 20% of the cells have an expected value less than 5) for categorical/dummy variables and Kruskal-Wallis test for continuous variables were performed.

DMT = disease-modifying therapy; ER = emergency room; HMO = health maintenance organization; MS = multiple sclerosis; POS = point of service; SD = standard deviation.